# Immunomodulators

This is a subcategory of Topical Agents.

## Length of Authorizations

365 Days

## Additional Criteria

### Step Therapy

Step Therapy Approval Criteria

1.  For a product requiring step therapy, there must have been an inadequate clinical response to no less than **two 30-day** trials of topical corticosteroids
2.  For a non-preferred medication, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than **30 days** of the preferred medication

### Other

Other Approval Criteria

Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:

-   Allergy to medications not requiring prior approval
-   Contraindication to or drug interaction with medications not requiring prior approval
-   History of unacceptable/toxic side effects to medications not requiring prior approval

### Clinical Information

-   Indicated for short-term and intermittent long-term treatment of atopic dermatitis if:
    -   Alternative, conventional therapies (such as topical corticosteroids) are deemed inadvisable because of potential risks, **or**
    -   There has been inadequate response or intolerance to alternative, conventional therapies (such as topical corticosteroids)
-   Elidel and Protopic 0.03% are indicated in patients 2 years old or older. Protopic 0.1% is indicated in adults only.
-   Opzelura is contraindicated for use in immunocompromised patients

AR - pimecrolimus and tacrolimus: a PA is required for patients younger than 2 years old

## Formulary

Topical Agents: Immunomodulators

### Preferred

| Preferred        |
| :--------------- |
| Elidel AR BvG ST |
| Protopic AR ST   |

### Non-Preferred

| Non-Preferred |
| :------------ |
| Eucrisa       |
| Opzelura      |
| Pimecrolimus  |

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=101)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=33)